AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen, Elevar Therapeutics - LARVOL DELTA

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. (PubMed, Lancet) - P1/2 | "This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable safety profile. These results support satri-cel as a new third-line treatment for advanced gastric or gastro-oesophageal junction cancer patients."

Journal • P2 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01). (ASCO 2025) - P1/2 | "For TPC arm, one of the standard of care (SOC) drugs (apatinib, paclitaxel, docetaxel, irinotecan or nivolumab) was given per physician's decision... This is the first confirmatory RCT of CAR T-therapy in solid tumors. Satri-cel demonstrated significant PFS improvement and an obvious OS benefit with a manageable safety profile. These results support satri-cel as a potential new SOC for advanced G/GEJC."

CAR T-Cell Therapy • Clinical • Metastases • P2 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor-Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma: A Systematic Review and Meta-analysis. (PubMed, Am J Clin Oncol) - "Camrelizumab, pembrolizumab, and nivolumab were the most commonly used ICIs, while apatinib was the most frequently used VEGF-targeted agent. ICIs plus VEGF-targeted agents showed promising activity, particularly when combined with chemotherapy. However, substantial interstudy heterogeneity limits definitive conclusions, highlighting the need for larger, standardized trials to optimize treatment strategies and identify patients most likely to benefit."

Checkpoint inhibition • Journal • Retrospective data • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Iparomlimab and Tuvonralimab (QL1706) Combined with Apatinib and Capecitabine for the Treatment of Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-Arm, Open-Label, Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (ASCO 2025) - P2 | "The combination of camrelizumab and apatinib demonstrated promising efficacy and manageable toxicity in chordoma treatment. Furthermore, CDKN2A alterations (CND or HD) were associated with poorer outcomes, providing a potential biomarker for therapeutic stratification."

Clinical • IO biomarker • Metastases • P2 data • Chordoma • CDKN2A

Camrelizumab Plus Apatinib for Locally Advanced or Metastatic Malignant Ocular Adnexal Tumors: A Multicenter, Multi-cohort, Single-arm Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ocular Melanoma • Oncology

BCTOP-L-M04: Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=145 | Active, not recruiting | Sponsor: Fudan University | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2025 ➔ Jul 2026

Enrollment closed • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial. (ASCO 2024) - P2 | "In conclusion, the combination of camrelizumab with apatinib showed promising activity and acceptable toxicity in advanced ACC patients who failed previous lines of therapy. Pre-treatment peripheral blood immune cell subsets could be regarded as potential predictors of efficacy. Given the promising clinical activity, the potential of camrelizumab with apatinib as first-line therapy for advanced ACC need further evaluated."

Clinical • Metastases • P2 data • Adrenal Cortex Carcinoma • Cardiovascular • Genito-urinary Cancer • Hypertension • Immunology • Oncology • Solid Tumor • CD4 • CD8 • CXCR3

A phase II trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib for resectable HNSCC: pathological response and vascular-immune crosstalk. (PubMed, Clin Cancer Res) - P4 | "Neoadjuvant camrelizumab plus apatinib demonstrated promising pathological activity and tolerability in resectable HNSCC. PD-L1 CPS, CTC clearance, and mIF-based tumour microenvironment profiling warrant investigation as candidate predictive biomarkers."

IO biomarker • Journal • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. (PubMed, Nat Commun) - P2 | "In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate the efficacy of a combination of ICI (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin) for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer...The toxicity and post-surgery complications are limited. These data support further validation of ICI- and antiangiogenesis-based neoadjuvant/conversion therapy in large randomized trials and provide candidate biomarkers."

Checkpoint block • Checkpoint inhibition • IO biomarker • Journal • Metastases • Tumor mutational burden • Gastric Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • MSI • PD-L1 • RREB1 • TMB

A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC). (ASCO-GU 2025) - P2 | "Camrelizumab plus apatinib combined with SBRT showed promising antitumor activity and manageable toxicity in pts with recurrent/metastatic nccRCC."

Clinical • Combination therapy • Metastases • P2 data • Genito-urinary Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Solid Tumor • CD4 • CD8 • FH

Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV) (ESMO 2023) - P2/3 | "Methods Pts with T3-4aN+M0 were randomized 1:1 to SOXRC (C 200 mg IV D1 + R 250 mg PO QD D1-21 + oxaliplatin 130 mg/m2 IV D1 + S-1 PO BID D1-14, Q3W) or SOX for 3 cycles pre/post D2 surgery, then R plus C (SOXRC) or S-1 (SOX) up to 17 cycles per investigator's choice...Preoperative grade ≥3 treatment-emergent adverse events occurred at rates of 36.3% (SOXRC) and 16.3% (SOX). Conclusions The trial showed perioperative C combined with R and chemo significantly improved pCR compared to chemo alone with a tolerable safety profile for localized resectable G/GEJ adenocarcinoma."

Clinical • Metastases • P3 data • P3 data: top line • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Stage 1 results of CAP 03-NEO demonstrated the potential of neoadjuvant camrelizumab, apatinib and temozolomide in pts with resectable stage II/III AM. The pNR result support advancing to stage 2 to further assess the efficacy and safety of this regimen in pts with stage III disease."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Melanoma • Oncology • Solid Tumor

Retlirafusp alfa Combined with Rivoceranib, With or Without Zeprumetostat, in Patients with Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy (ESMO 2026) - No abstract available

Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor

A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Jin Ying | Trial primary completion date: Jun 2026 ➔ Dec 2026

Biomarker • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial. (ASCO 2026) - P3 | "Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT05320692 Background: The combination of C (anti–PD-1 antibody) + R (VEGFR2 tyrosine kinase inhibitor) significantly improved progression-free survival (PFS) and overall survival (OS) vs sorafenib as first-line treatment for advanced HCC, and improved event-free survival vs surgery alone as perioperative treatment for resectable HCC. C+R+TACE provided statistically significant and clinically meaningful improvement in PFS vs TACE, with manageable safety, supporting this regimen as a potential new treatment option for TACE-eligible uHCC. Follow-up for OS is ongoing. PFS outcomes (ITT set)."

Clinical • P3 data • Cardiovascular • Hepatocellular Cancer • Hypertension • Oncology • Solid Tumor

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC (clinicaltrials.gov) - P2 | N=128 | Recruiting | Sponsor: The First Affiliated Hospital of Bengbu Medical University | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Sep 2025 ➔ Sep 2027

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis (ESMO 2026) - No abstract available

Clinical • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages. (PubMed, Transl Cancer Res) - "Akk depletion accompanies an apatinib-resistant HCC phenotype and Akk-centered microbial modulation may help counteract resistance by reshaping macrophage-associated antitumor immunity. These findings support further validation of Akk-derived signals in community-level microbiome models and clinically relevant HCC settings."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • NFKBIA

Irinotecan Liposome Plus Vincristine and Apatinib for Relapsed/Refractory Adult Rhabdomyosarcoma: An Exploratory Study (ESMO 2026) - No abstract available

Clinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

Camrelizumab Plus Apatinib Combined with Gemcitabine and Oxaliplatin (GEMOX) as First-Line Treatment for Advanced Biliary Tract Cancer (BTC): A Biomarker Exploratory Phase II Trial (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (SABCS 2025) - P2 | "The treatment regimen consisted of camrelizumab (200 mg intravenously every 2 weeks, 12 cycles), apatinib (250 mg orally daily), and alternating chemotherapy [nab-paclitaxel (d1, 8, 15 every 4 weeks) for 4 cycles and epirubicin plus cyclophosphamide (every 2 weeks) for 4 cycles]. From June 2023 to April 2024, 35 patients were enrolled, of whom 1 patient withdrew due to adverse reaction intolerance. In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization."

Biomarker • Clinical • IO biomarker • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CXCL1 • IL17A • IL18 • MMP7 • PD-L1 • TP53

Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: a prospective phase II clinical study (EANO 2026) - P2 | "Camrelizumab in combination with apatinib neoadjuvant therapy showed excellent efficacy in recurrent high-grade gliomas, and was superior to PD1 inhibitor monotherapy neoadjuvant treatment in rGBM patients."

Clinical • Combination therapy • P2 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Gliosarcoma • High Grade Glioma • Oligodendroglioma • Oncology • Sarcoma • Solid Tumor • KDR

Adebrelimab Plus Apatinib for Maintenance Treament of ES-SCLC After First-Line Induction With Adebrelimab Plus Chemotherapy (CLOG2402-ADAPT) (IASLC-WCLC 2026) - "Methods : Patients with ES-SCLC who had not progressed after 4-6 cycles of 1L induction therapy with adebrelimab plus platinum-etoposide were eligible to enter the maintenance phase. No treatment-related deaths occurred. Conclusions : Adebrelimab plus apatinib showed clinically meaningful antitumor activity and acceptable tolerability as 1L maintenance therapy in patients with ES-SCLC following induction with adebrelimab plus chemotherapy."

Clinical • Gastrointestinal Disorder • Interstitial Lung Disease • Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor